199 related articles for article (PubMed ID: 34023950)
1. Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey.
Alzahrani M; Clemons M; Sienkiewicz M; Shrem NS; McGee SF; Vandermeer L; Sehdev S; Savard MF; Awan A; Canil C; Hutton B; Pond G; Saunders D; Ng T
Support Care Cancer; 2021 Nov; 29(11):6903-6912. PubMed ID: 34023950
[TBL] [Abstract][Full Text] [Related]
2. Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey.
AlZahrani M; Clemons M; Vandermeer L; Sienkiewicz M; Awan AA; Hutton B; Pond GR; Ng TL
J Bone Oncol; 2021 Feb; 26():100339. PubMed ID: 33294318
[TBL] [Abstract][Full Text] [Related]
3. Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
Anton A; Wong S; Shapiro J; Weickhardt A; Azad A; Kwan EM; Spain L; Gunjur A; Torres J; Parente P; Parnis F; Goh J; Semira MC; Gibbs P; Tran B; Pezaro C
Eur J Cancer; 2021 Nov; 157():485-492. PubMed ID: 34344533
[TBL] [Abstract][Full Text] [Related]
4. Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.
Alzahrani M; Stober C; Liu M; Awan A; Ng TL; Pond G; Alshamsan B; Vandermeer L; Clemons M
Support Care Cancer; 2022 May; 30(5):3977-3984. PubMed ID: 35059864
[TBL] [Abstract][Full Text] [Related]
5. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.
Clemons M; Ong M; Stober C; Ernst S; Booth C; Canil C; Mates M; Robinson A; Blanchette P; Joy AA; Hilton J; Aseyev O; Pond G; Jeong A; Hutton B; Mazzarello S; Vandermeer L; Kushnir I; Fergusson D;
Eur J Cancer; 2021 Jan; 142():132-140. PubMed ID: 33023785
[TBL] [Abstract][Full Text] [Related]
6. Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer.
Mitchell AP; Meza AM; Panageas KS; Lipitz-Snyderman A; Farooki A; Morris MJ
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):126-132. PubMed ID: 35798857
[TBL] [Abstract][Full Text] [Related]
7. Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment.
Blas L; Shiota M; Matsumoto T; Hori Y; Nakamura M; Seki N; Kuroiwa K; Yokomizo A; Morokuma F; Kiyoshima K; Eto M
Int J Urol; 2023 Nov; 30(11):1029-1034. PubMed ID: 37501328
[TBL] [Abstract][Full Text] [Related]
8. Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
Mitchell AP; Mishra Meza A; Panageas KS; Lipitz-Snyderman A; Bach PB; Morris MJ
J Natl Cancer Inst; 2022 Mar; 114(3):419-426. PubMed ID: 34597380
[TBL] [Abstract][Full Text] [Related]
9. Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review.
Ng TL; Tu MM; Ibrahim MFK; Basulaiman B; McGee SF; Srikanthan A; Fernandes R; Vandermeer L; Stober C; Sienkiewicz M; Jeong A; Saunders D; Awan AA; Hutton B; Clemons MJ
Support Care Cancer; 2021 Feb; 29(2):925-943. PubMed ID: 32535678
[TBL] [Abstract][Full Text] [Related]
10. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.
Smith MR; Coleman RE; Klotz L; Pittman K; Milecki P; Ng S; Chi KN; Balakumaran A; Wei R; Wang H; Braun A; Fizazi K
Ann Oncol; 2015 Feb; 26(2):368-74. PubMed ID: 25425475
[TBL] [Abstract][Full Text] [Related]
11. Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer.
Clemons M; Liu M; Stober C; Pond G; Jemaan Alzahrani M; Ong M; Ernst S; Booth C; Mates M; Abraham Joy A; Aseyev O; Blanchette P; Vandermeer L; Tu M; Thavorn K; Fergusson D;
J Bone Oncol; 2021 Oct; 30():100388. PubMed ID: 34567960
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Tanaka R; Yonemori K; Hirakawa A; Kinoshita F; Takahashi N; Hashimoto J; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Fujimoto M; Fujiwara Y; Tamura K
Oncologist; 2016 Apr; 21(4):508-13. PubMed ID: 26975863
[TBL] [Abstract][Full Text] [Related]
13. De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis.
Awan AA; Hutton B; Hilton J; Mazzarello S; Van Poznak C; Vandermeer L; Bota B; Stober C; Sienkiewicz M; Fergusson D; Shorr R; Clemons M
Breast Cancer Res Treat; 2019 Aug; 176(3):507-517. PubMed ID: 31079283
[TBL] [Abstract][Full Text] [Related]
14. Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer.
Mitchell AP; Nemirovsky D; Mishra Meza A; Chakraborty N; Persaud S; Farooki A; Morris MJ
JCO Oncol Pract; 2024 Mar; 20(3):393-400. PubMed ID: 38190588
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey.
McGee S; Alzahrani M; Vandermeer L; Cole K; Larocque G; Awan A; Hutton B; Pond G; Saunders D; Clemons M
Breast Cancer Res Treat; 2021 Jun; 187(2):477-486. PubMed ID: 33755864
[TBL] [Abstract][Full Text] [Related]
16. Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases.
McKay R; Haider B; Duh MS; Valderrama A; Nakabayashi M; Fiorillo M; Ristovska L; Wen L; Kantoff P
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):276-282. PubMed ID: 28220804
[TBL] [Abstract][Full Text] [Related]
17. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer.
Tu MM; Clemons M; Stober C; Jeong A; Vandermeer L; Mates M; Blanchette P; Joy AA; Aseyev O; Pond G; Fergusson D; Ng TL; Thavorn K
Curr Oncol; 2021 May; 28(3):1847-1856. PubMed ID: 34068083
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
[TBL] [Abstract][Full Text] [Related]
20. Determinants of Bone-Modifying Agent Prescribing for Metastatic Castration-Resistant Prostate Cancer in a National Health Care Delivery System.
Nguyen CB; Kobe C; Kumbier KE; Bauman J; Burns JA; Tsao PA; Sparks JB; Skolarus TA; Caram MEV
JCO Oncol Pract; 2024 Jan; 20(1):59-68. PubMed ID: 38085028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
